Drug Database
AN

anakinra (PerkinRA)

✓ Approved

PersisGen Par · IL1R1 · 重组蛋白

什么是 anakinra?

anakinra 是一种重组蛋白,由PersisGen Par研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Intravenous (IV)、Subcutaneous Injection。

药物档案

商品名PerkinRA
公司PersisGen Par
药物类别重组蛋白
分子靶点IL1R1
给药途径Injectable (Others), Intravenous (IV), Subcutaneous Injection
状态Approved

作用机制

分子靶点

anakinra 作用于 1 个分子靶点:

IL1R1interleukin 1 receptor type 1 (P80, CD121A)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

anakinra 针对 11 个适应症,涉及 5 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersRheumatoid arthritis✓ Approved
Musculoskeletal and connective tissue disordersStill's disease✓ Approved
Musculoskeletal and connective tissue disordersJuvenile idiopathic arthritis✓ Approved
Congenital, familial and genetic disordersChronic infantile neurological cutaneous and articular syndrome✓ Approved
Congenital, familial and genetic disordersMuckle-Wells syndrome✓ Approved

注册免费账户还可查看另外 6 个适应症

免费注册查看全部适应症 →

相关研究文献

PubMedEBioMedicine2026-11-18

Inflammatory protein trajectories and severe respiratory failure in COVID-19: a secondary analysis of the SAVE-MORE randomised trial.

Keur Nick N, Stylianakis Emmanouil E, Ricaño-Ponce Isis I, Rapti Vassiliki V et al.

Severe COVID-19 is characterised by maladaptive host inflammation. In the SAVE-MORE trial (EudraCT no. 2020-005828-11; ClinicalTrials.gov NCT04680949), suPAR-guided anakinra treatment reduced mortality and progression to severe respiratory failure (SRF), but the underlying molecular mechanisms remain unclear. We performed longitudinal proteomic profiling (Olink Inflammation panel, 67 proteins) in 587 SAVE-MORE participants (400 treated with anakinra and 187 with placebo), of whom 453 had samples at all three time points (baseline, Day 4, and Day 7). Analyses aimed to (i) identify baseline predictors of SRF, (ii) define inflammatory trajectories using mixed-effects models, and (iii) characterise proteomic changes at SRF onset. Cox models identified prognostic markers, validated in an independent anakinra-treated cohort from the SAVE trial (n = 153). Multivariate Cox regression models adjusted for sex, age, BMI, and dexamethasone treatment showed that baseline IL-6 concentrations predicted SRF across both treatment arms (placebo HR = 1·99, CI: 1·31-3·02; anakinra HR = 2·12, CI: 1·56-2·87), while PD-L1 predicted SRF only in the placebo group (HR = 2·75, CI: 1·79-4·24). Anakinra allocation was associated with changes in inflammatory trajectories related to SRF progression. Patients developing SRF showed sustained activation marked by elevated concentrations of IL-6, MCP-1/3, EN-RAGE, and PD-L1, whereas SRF-free patients had higher levels of proteins linked to regulatory and adaptive immunity, including CD6, CD244, TRAIL, TNF-B, and FLT3L. Event-aligned analyses showed an acute inflammatory surge at SRF onset involving IL-6, CXCL5, OSM, and VEGFA, which was significantly attenuated by anakinra. Results were further confirmed in the SAVE cohort. Progression to SRF was associated with an inflammatory amplification programme involving cytokine, chemokine, tissue-injury, and immune-checkpoint pathways. Anakinra allocation was associated with smaller changes in proteins associated with inflammatory amplification and acute inflammatory changes accompanying respiratory deterioration. These findings provide biological context for the clinical benefit observed in the SAVE-MORE trial. Hellenic Institute for the Study of Sepsis (sponsor) and Swedish Orphan Biovitrum (funder).

PMID 43050905
阅读全文 →
PubMedExpert opinion on biological therapy2026-11-15

Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study.

Kara Çanlıoğlu Neslihan N, Atamyıldız Uçar Sıla S, Tunce Eray E, Sözeri Betül B

Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences. This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41). Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks. Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.

PMID 43033152
阅读全文 →
PubMedCureus2026-11-15

Haemophagocytic Lymphohistiocytosis Presenting With a Renal Infarct of Unclear Aetiology and Persistent Fever: A Diagnostic Dilemma.

Barud Yasmin Y

Haemophagocytic lymphohistiocytosis (HLH) is a rare and potentially fatal hyperinflammatory syndrome characterised by excessive immune activation and progressive multisystem dysfunction. Diagnosis in adults can be challenging due to overlap with infection and malignancy. This case is based on a gentleman in his mid-30s who presented with acute right-sided flank pain and a right renal infarction. From the second day of admission, he developed persistent pyrexia despite antipyretic therapy and broad-spectrum antibiotics. Over the following two weeks, he developed anaemia, thrombocytopenia, marked hyperferritinaemia, and hypertriglyceridaemia. An H-score of 220 supported the diagnosis of HLH, and his case met 5/8 of the HLH-2004 criteria. Thrombophilia, antiphospholipid, and vasculitis testing were negative; haematology considered the infarct likely arterial, although no cause was identified. A blood culture grew gram-positive cocci in clusters; repeat cultures following readmission were negative after treatment was commenced. Bone marrow examination showed no malignancy or convincing haemophagocytosis. Following multidisciplinary review, treatment with intravenous methylprednisolone and anakinra was associated with clinical and biochemical improvement. This case highlights the need to consider HLH in patients with persistent fever, falling blood counts, and markedly elevated ferritin despite treatment for an alternative acute diagnosis.

PMID 43032324
阅读全文 →
PubMedPostgraduate medicine2026-11-14

Optimizing recurrent pericarditis management through IL-1 inhibition and the evolving multidisciplinary pharmacist-led care to comprehensive patient management.

Al-Taie Anmar A, Atal Deniz D

Recurrent pericarditis is a relapsing inflammatory disorder driven by overlapping autoimmune and autoinflammatory mechanisms, with interleukin-1 (IL-1) playing a central role in disease pathogenesis. Although first-line treatment with nonsteroidal anti-inflammatory drugs and colchicine, with the use of corticosteroids when necessary, effectively controls disease in most patients, a subset remains refractory or corticosteroid-dependent, experiencing frequent relapses despite optimal conventional therapy. Biologic agents targeting IL-1 in clinical applications, including anakinra and rilonacept, have demonstrated rapid symptom relief, reduced recurrence rates, decreased corticosteroid exposure, and favorable safety profiles, particularly in patients with elevated inflammatory markers and clinical features consistent with an autoinflammatory phenotype. Pharmacists are well positioned to address these gaps through medication review, patient education, interaction screening for biologics, vaccination counseling, and reinforcement of exercise restriction. Therefore, integrating pharmacists into multidisciplinary pericarditis care pathways can improve clinical outcomes, reduce recurrence rates, and enhance overall quality of life. This review provides an extensive overview of the current evidence supporting the use of IL-1 inhibitors in the treatment of recurrent pericarditis and explores the expanding role of pharmacists within multidisciplinary care teams. It also emphasizes strategies to optimize pharmacotherapy, reduce reliance on corticosteroids, enhance medication adherence and safety, and ultimately decrease the risk of disease recurrence.

PMID 43031356
阅读全文 →
PubMedClinical rheumatology2026-11-10

Clinical and laboratory outcomes during sequential anakinra and canakinumab treatment in familial Mediterranean fever: a retrospective within-patient study.

Kaya Mehmet Nur MN, Kılıç Özlem Ö, Tecer Duygu D, Yılmaz Sedat S

To describe clinical, laboratory, disease-severity, and safety outcomes after switching from anakinra to canakinumab in FMF patients who required treatment change because of inadequate response and/or intolerance to anakinra. This retrospective within-patient sequential cohort study included 26 adult FMF patients who received anakinra followed by canakinumab between January 2017 and September 2024. Demographic, clinical, genetic, laboratory, treatment-related data, and reasons for switching were obtained from medical records. Annual attack count, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), 24-h proteinuria, International Severity Score for FMF (ISSF), attack manifestations, and adverse events were evaluated using paired analyses. The median age was 35.0 years, and 13 patients (50.0%) were female. During canakinumab treatment, annual attack count [2.0 (1.0-3.0) vs 4.0 (4.0-4.0), p < 0.001], CRP [5.0 (4.0-6.0) vs 20.0 (16.2-61.2) mg/L, p < 0.001], ESR [8.5 (5.5-12.0) vs 35.5 (27.5-63.8) mm/h, p < 0.001], 24-h proteinuria [125.0 (96.8-217.5) vs 310.0 (204.0-702.2) mg/day, p < 0.001], and ISSF score [1 (1-2) vs 2 (2-3), p = 0.002] were significantly lower than during anakinra treatment. Fever and peritonitis were also less frequent during canakinumab treatment. The primary reasons for switching were inadequate response in 18 patients (69.2%) and intolerance or adverse events leading to treatment discontinuation in 8 patients (30.8%). In this small retrospective switch cohort, canakinumab treatment was associated with lower attack frequency, lower inflammatory markers, and lower retrospectively calculated ISSF scores after switching from anakinra. Proteinuria findings remain exploratory. These findings suggest that canakinumab may be a useful subsequent option in selected difficult-to-treat FMF patients, but prospective controlled studies are needed to confirm these observations.

PMID 43004123
阅读全文 →
PubMedEuropean journal of clinical investigation2026-11-09

Clinical-Immunological Phenomapping in Recurrent Pericarditis: Disentangling Biological Traits, Inflammatory State and Treatment Exposure.

Wu M A MA, Kessel C C, Colombo R R, Fuehner S S et al.

Phenotype-oriented management is increasingly advocated in recurrent pericarditis (RP), but it remains unclear whether clinically recognizable phenotypes reflect underlying disease biology or are shaped by current inflammation and treatment exposure. We used multidimensional phenomapping to investigate this heterogeneity. We analysed 101 patients with idiopathic RP from the multicenter PERIPLO cohort. Factor analysis of mixed data followed by hierarchical clustering defined the index solution. Robustness was assessed across alternative specifications and models excluding treatment, inflammatory state or the IL-1Ra axis. Three clinical-immunological patterns emerged: a predominantly remission-state, anakinra-treated group; a predominantly remission-state group largely managed without IL-1 blockade; and an active inflammatory group enriched for anti-IL-1Ra autoantibodies and characterized by markedly reduced measured IL-1Ra. The two antibody-negative groups were extensively reorganized after treatment variables were removed, whereas exclusion of the IL-1Ra axis nearly abolished agreement with the original partition. In contrast, anti-IL-1Ra positivity remained consistently associated with active inflammation and very low measured IL-1Ra. In this cohort, the phenotypic heterogeneity of RP was better represented as a clinical-immunological spectrum shaped by inflammatory state and treatment exposure than as discrete, stable endotypes. The anti-IL-1Ra-associated inflammatory signature was the most internally consistent biological signal. These exploratory findings require external validation, and longitudinal multidimensional phenomapping should test whether this signature can inform patient management.

PMID 43001649
阅读全文 →

注册免费账户还可查看另外 3242 篇文献

免费注册查看全部文献 →

了解更多anakinra